Biomarkers & diagnostics: Growing influence on drug development for NAFLD/NASH

Biomarkers and diagnostics are playing an ever-increasing role in drug development. Biomarkers as candidate diagnostics are becoming increasingly important in complex, multifactorial chronic diseases including non-alcoholic fatty liver disease (fat accumulation in the liver not due to alcohol overconsumption, or NAFLD) and non-alcoholic steatohepatitis (NASH).